LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "originator" as a keyword



Photo by schluditsch from unsplash

Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Neurology"

DOI: 10.1007/s00415-019-09234-y

Abstract: ObjectivesInfliximab is increasingly used to treat neurosarcoidosis. We aimed to determine the efficacy and tolerance of an infliximab biosimilar for treating neurosarcoidosis.MethodsWe conducted a retrospective single-center study to describe the efficacy, safety and immunogenicity of… read more here.

Keywords: originator; treatment; efficacy; treating neurosarcoidosis ... See more keywords
Photo from wikipedia

Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience

Sign Up to like & get
recommendations! Published in 2018 at "Scandinavian Journal of Gastroenterology"

DOI: 10.1080/00365521.2018.1464203

Abstract: Abstract Objectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim to assess the efficacy and safety of switching from originator infliximab… read more here.

Keywords: response; originator; efficacy; infliximab originator ... See more keywords
Photo by paxsonwoelber from unsplash

Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

Sign Up to like & get
recommendations! Published in 2022 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2022.2070428

Abstract: ABSTRACT Background Pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional drugs in psoriasis are lacking. Research design and methods To assess the cost per responder of adalimumab biosimilars versus the… read more here.

Keywords: cost per; responder; cost; adalimumab biosimilars ... See more keywords
Photo from wikipedia

Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.

Sign Up to like & get
recommendations! Published in 2021 at "Inflammatory bowel diseases"

DOI: 10.1093/ibd/izab027

Abstract: BACKGROUND Few data are currently available about SB5 in inflammatory bowel diseases (IBD). The aim of this study was to assess the effectiveness and safety of SB5 in a cohort of patients with IBD in… read more here.

Keywords: inflammatory bowel; originator; safety; bowel diseases ... See more keywords
Photo by atikahakhtar from unsplash

Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab

Sign Up to like & get
recommendations! Published in 2018 at "British Journal of Dermatology"

DOI: 10.1111/bjd.16269

Abstract: Psoriasis vulgaris is a chronic, inflammatory skin disease characterized by a dysregulated immune response and it is associated with substantial systemic comorbidities. Biological drugs such as tumour necrosis factor (TNF)‐α inhibitors can ameliorate the disease… read more here.

Keywords: phosphorylation intracellular; originator; signalling molecules; molecules peripheral ... See more keywords
Photo from wikipedia

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.

Sign Up to like & get
recommendations! Published in 2021 at "Clinical and translational science"

DOI: 10.1111/cts.13131

Abstract: Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX… read more here.

Keywords: originator; switch; safety; efficacy ... See more keywords
Photo from wikipedia

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?

Sign Up to like & get
recommendations! Published in 2022 at "Dermatologic Therapy"

DOI: 10.1111/dth.15803

Abstract: In the last years, adalimumab biosimilars have represented a commonly used alternative to the originator agent in the treatment of moderate to severe hidradenitis suppurativa. As of today, studies investigating the switch from adalimumab originator… read more here.

Keywords: adalimumab originator; switch; switching adalimumab; originator biosimilars ... See more keywords
Photo by enginakyurt from unsplash

FRI0329 Efficacy and safety of infliximab originator in patients with takayasu arteritis within the RTU (temporary recommendation of use) in france

Sign Up to like & get
recommendations! Published in 2017 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2017-eular.1793

Abstract: Background The benefit/risk ratio of infliximab in refractory patient with Takayasu arteritis (TA) is assumed to be favorable, based on retrospective studies with limited sample size [1, 2] in which infliximab has been prescribed off-label.… read more here.

Keywords: originator; infliximab originator; efficacy; takayasu arteritis ... See more keywords
Photo by rojekilian from unsplash

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

Sign Up to like & get
recommendations! Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-214374

Abstract: To date, all available data regarding the switch from bio-originator to its biosimilar are reassuring, and the switch has been recommended as a shared patient–physician decision in recent consensus-based recommendations.1 In particular, the Norway's infliximab… read more here.

Keywords: originator; long term; term follow; originator infliximab ... See more keywords
Photo by samsungmemory from unsplash

AB0401 SWITCH FROM ETANERCEPT ORIGINATOR TO ETANERCEPT BIOSIMILAR: DATA FROM REAL LIFE

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.7809

Abstract: Background: Biosimilars of antiTNF-α are now available for the treatment of arthritis. There are a lot of data about maintenance of clinical efficacy after switching from originator to biosimilar but also reports about flares and… read more here.

Keywords: originator; etanercept originator; switch; disease ... See more keywords
Photo by schluditsch from unsplash

FRI0377 IDENTICAL TWO-YEAR TREATMENT RETENTION OF ORIGINATOR AND BIOSIMILAR INFLIXIMAB. RESULTS OF A NORDIC COLLABORATION INCLUDING 1319 PATIENTS WITH SPONDYLOARTHRITIS

Sign Up to like & get
recommendations! Published in 2019 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2019-eular.994

Abstract: Background The first infliximab biosimilar (CT-P13) was introduced in Europe in 2014, followed by a rapid, but differential, uptake across the Nordic countries [1]. Pre and post-marketing randomized controlled trials have shown similar efficacy and… read more here.

Keywords: p13; treatment; originator; inf ... See more keywords